`` The data for Celebrex is robust and exceeds , in the length of patients in studies and in the size of studies , the data Vioxx has , '' she said .
`` The data for Celebrex is robust and exceeds , in the length of patients in studies and in the size of studies , the data Vioxx has , '' she said .
After the presentation in France , Graham discussed the issue with his supervisor , the statement said .
But taking the drug off the market , he said , was the right thing , too .
Information from the earlier study went on the Vioxx label in April 2002 , according to the FDA .
